The implantable cardiac defibrillator (ICD) has been an effective tool for prevention of sudden cardiac death (SCD) in populations at high risk for life-threatening sustained ventricular tachycardia (VT) and ventricular fibrillation (VF). However, ICD implantation is dependent on defining ventricular substrate, evaluating the future risk of SCD and estimation of the patient's overall survival. The ability to predict risk of SCD is often difficult. If ventricular dysfunction (a surrogate marker for the risk of SCD) improves, ICD therapy may not be indicated. The wearable cardiac defibrillator (WCD) provides an option for protection during this vulnerable period when the risk of SCD is unclear. It combines an electrocardiogram-monitoring system with an external automatic defibrillator. The WCD can be a safe and effective tool for prevention of VT/VF related SCD events and is used in a variety of clinical situations where the risk of SCD is changing. Such situations include the early phase after acute myocardial infarction with poor left ventricular function (35%), after acute coronary revascularization procedures and reduced left ventricular ejection fraction (35%), acute heart failure and non-ischemic cardiomyopathy of uncertain duration and prior to medical therapy initiation. The WCD also has a role in patients waiting for heart transplantation or who need a ventricular-assist device and those who have an acute contra-indication to implantation such as active infection. This review discusses the technical aspects of the WCD, its potential clinical application and summarizes the currently available data on the WCD in different populations and future directions.
Introduction
The implantable cardiac defibrillator (ICD) has been used to prevent sudden cardiac death (SCD) among patients with a high risk for lifethreatening sustained ventricular tachycardia (VT) and ventricular fibrillation (VF). Based on available data from clinical trials, current European and American guidelines recommend ICD implantation for patients with significant risk of SCD. [1] [2] [3] However, there are a number of patients at risk for SCD either awaiting a work-up for reversible causes of SCD or with acute contraindications to ICD implantation. The wearable cardiac defibrillator (WCD) is a potential option for patients who are at significant risk for VT/VF but are not immediate candidates for ICD implantation. Recommendations for the WCD is largely based on data registries and smaller single or multicentre studies. In a previous review, Klein et al. provide us with an extensive insight into the technical aspects of the WCD and a general literature review. 4 In the present review, we hope to update available data on the use of WCDs and report society recommendations and discuss future perspectives.
The WCD system
The LifeVest TM (ZOLL Lifecor Corp., Pittsburgh, PA, USA) is the only wearable cardiac defibrillator system available for patients at risk of SCD and was first approved by the FDA in 2002. The system consists of two main components which include a garment and a monitor ( Figure 1 ). The garment is worn under the patient's clothing and contains electrodes that help record a signal for arrhythmia detection. The monitor is usually worn around the waist or from a shoulder strap and continuously monitors the patient's rhythm. The garment contains an elastic belt and shoulder straps that carry four sensing electrodes and three defibrillator electrodes ( Figure 1) . The defibrillator electrodes exude gel automatically just before delivery of a shock.
Microampere alternating current is used to check electrode contact as in conventional monitoring systems. The monitor contains the battery and defibrillator itself, an alarm system, and response buttons. The device also acts as a loop recorder and continuously records and transmits data on tachyarrhythmias and bradyarrhythmias. It does not have capabilities for backup bradycardia pacing or for antitachycardia overdrive pacing. The device may be programmed to different VT or VF zones with different response times (time from detection to defibrillation sequence activation) and shock energy (between 75 and 150 J, biphasic). The WCD is prone to a higher risk of motion-related sensing artifacts than an implanted ICD, the system is equipped with special noise reduction algorithms. There is a sensing function to detect electrodes falling off. This algorithm detects if the signal from one lead is suboptimal, then it reverts to single channel mode, ignoring the inputs from the faulty channel. There is also an alarm system consists of a vibration signal, two successive sound alarms (low and high volume), and a verbal warning that a shock is imminent. As long as the response buttons are pressed, the WCD withholds therapy. Thus, conscious patients hearing (or sensing) the alarm system may prevent themselves from being shocked inappropriately (as a result of noise artifacts or hemodynamically stable VTs). At the same time, the patient is instructed to sit or lie down to avoid injury in the event of loss of consciousness.
In case of a rapid life-threatening VT, the patient eventually loses consciousness, the response buttons are thereby released, defibrillation inhibition is withdrawn, and lifesaving shocks are delivered. Just before delivering the shock, the defibrillation electrodes release a gel to reduce electrical impedance and the device gives an announcement for bystanders to keep off the patient. Electrocardiogram (ECG) records from 30 s prior to the alarm until 15 s after the alarm can be stored and sent to a secure server by modem later. Patients can also initiate manual ECG recordings. If the WCD detects asystole, it gives an announcement to call the ambulance so that bystanders can respond. The total time from VT/VF initiation to shock delivery is <1 min and includes arrhythmia detection, alarm system activation, and charging ( Figure 2) . If the arrhythmia is redetected after defibrillation, the cycle is repeated, and up to five shocks can be delivered for a single event. Patients are instructed to seek immediate medical evaluation after receiving a WCD shock. Evaluation includes a review of the arrhythmias that trigger the shock, which are automatically recorded and stored. Figures 3-6 represent examples of appropriate and inappropriate detection and therapy from the LifeVest TM device.
Current guidelines and the gaps in knowledge
Clinical trials on SCD have consistently demonstrated that the highest risk for SCD is among patients with severely depressed LV function. Thus, guidelines on primary prevention of SCD recommend implantation of an ICD in patients with severely depressed left ventricular ejection fraction (LVEF) of 35% with Class II/III heart failure (HF) symptoms (Class I recommendation). In order to ensure that the LV dysfunction is irreversible and the risk for SCD is permanent, current guidelines recommend a waiting period to allow for potential improvement in LV function on guideline directed medical therapy (GDMT). This waiting period depends on the cause for LV dysfunction. Among patients with ischemic cardiomyopathy (ICM) occurring as a result of a recent myocardial infarction (MI), a waiting period of least 3- revascularization has been recommended. Similarly, for patients with non-ischemic cardiomyopathy (NICM), a waiting period of 3-months on GDMT has been suggested to allow for improvement of LV function. This leaves a large time gap, the waiting period between the initial diagnosis of a depressed LV function and reassessment of LV function after GDMT where patients are unprotected and at a high risk for SCD.
The basis for postponing ICD implantation under these circumstances is that with institution of optimal medical therapy/GDMT or interventional therapies including coronary artery bypass grafting (CABG) and percutaneous cardiac intervention (PCI) a substantial portion of patients experience significant myocardial recovery and improved ventricular function.
Studies have demonstrated that 50% of patients demonstrate partial or complete recovery of LVEF at 3 months after AMI after institution of HF therapies or revascularization [5] [6] [7] [8] and approximately 50%
of patients with newly diagnosed NICM will demonstrate a 10% improvement in LVEF with the initiation of GDMT. [9] [10] [11] However, current data still leave some gaps in our knowledge about the benefit of ICD implantation during these waiting periods. There are some data assessing the potential benefit of ICD implantation in the immediate post-MI patients with a low LVEF. In the Valsartan in Acute Myocardial Infarction Trial (VALIANT) trial 12 patients with an ejection fraction of 30% post-MI, 21% of the SCD or resuscitated cardiac arrest events occurred within the first 30 days after MI and about 51% of these were arrhythmic. 13 The Immediate Risk Stratification Improves Survival (IRIS) trial mandated an LVEF 40% and a resting heart rate >90 b.p.m. or non-sustained VT >150 b.p.m. on Holter monitoring early post-MI and showed no benefit of early ICD implantation. 14 However, these trials recruited highly selected patients who often had additional risk factors for increased all-cause mortality. For instance, the IRIS trial screened 62 944 unselected post-MI patients to enrol 898 (1.4% of the total screened). The DINAMIT trial was a randomized trial comparing ICD and no ICD in patients with recent MI and LVEF < 35% and demonstrated no difference in all-cause mortality. 15 The overall survival was not different largely because patients in the ICD group had a higher risk of non-arrhythmic death (hazard ratio 1.72 ; P ¼ 0.05) suggesting that patients with risk factors for SCD are also at high risk of death from other causes. However, the risk of arrhythmic death was lower in the ICD group (hazard ratio 0.42; P ¼ 0.009).
There are no available randomized trials comparing early ICD implantation (i.e. within 3 months) with standard medical therapy in NICM. A subgroup analysis of the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Trial, 16 demonstrated that among patients with a recent diagnosis of cardiomyopathy (within 3 months), mortality was 48% lower in ICD recipients randomized within 9 months of initial diagnosis (9.2% vs. 17 .7%; P ¼ 0.058). 9 These findings might suggest that benefit from a primary prevention ICD is not time dependent either in ICM or NICM and that the risk for VT/VF related SCD exists for these patients at any given point in time after their index event or diagnosis.
Patients with prior history of VT/VF (secondary prevention) in the absence of reversible causes are generally considered candidates for ICD implantation based on current guidelines as long as they have a life expectancy with a reasonable quality of life of at least 1-year. However, patients who have Class IV HF and are being evaluated for advanced HF therapies such as a left ventricular assist device and/or cardiac transplant need protection from SCD during this period. Acute patient clinical conditions (e.g. active blood stream infections) may prevent or delay ICD implantation among patients with secondary prevention indication and these patients would be unprotected as well. Finally, the patients with an ICD requiring system extraction/ explantation due to a cardiac device infection (CDI) would be unprotected for variable amounts of time until antibiotic therapy is completed and it is safe to re-implant an ICD. All of the above category of patients could potentially benefit from a WCD to offer them protection during this vulnerable period until a permanent ICD can be implanted/re-implanted.
Based on the above, the current society guidelines incorporate slightly different recommendations regarding the use of the WCD among different patient populations ( Table 1) .
Guidelines for the use of the WCD are summarized in Table 1 and  below: (1) AHA advisory (endorsed by the HRS) 17 
Available data on WCDs
The Lifevest TM was first approved by the U.S. Food and Drug
Administration in 2002 on the basis of two parallel trials, the Wearable Defibrillator Investigative Trial (WEARIT) and Bridge to ICD in Patients at Risk of Arrhythmic Death (BIROAD) studies which were later combined into one trial at the request of the FDA. 19 The WEARIT study enrolled patients with symptomatic HF (NYHA class III-IV) and LVEF < 30% and were considered high risk but did not meet criteria for an ICD. The BIROAD study enrolled patients who were perceived to be at high risk for sudden death and within 4 months of an MI or surgical revascularization which included but not limited to ventricular arrhythmias within 48 h of CABG, LVEF < 30% after CABG, syncope after CABG, and patient refusal of an ICD. 
Safety and efficacy of WCD Early post-MI patients
Current device guidelines require waiting periods of either 40 days or 3 months post-MI before implanting an ICD, depending on whether or not acute revascularization was undertaken. Various prospective and retrospective trials have assessed the benefit of the WCD in patients who are early post-MI. One of the largest studies is in post-MI patients from Epstein et al. 20 This study assessed patients with a recent MI (within 3 months post-MI) with LVEF 35% in 8453 patients. A total of 133 patients (1.6%) received 309 appropriate shocks and 91%
were resuscitated from a ventricular arrhythmia. The risk of SCD was highest in the first month of WCD use (median time from the index MI to WCD therapy was 16 days). Of the treated patients, 75% received treatment in the first month, and 96% within the first 3 months of use. Shock success resulting in survival was 84% in nonrevascularized patients and 95% in revascularized patients. The European experience with the WCD was reported by Klein et al. who reported the German experience of WCDs in a national cohort of 354 patients, 138 of which (39%) were hospitalized for AMI with LVEF 35% and received the WCD within 3-5 days after AMI. 21 About 65% underwent immediate PCI; the mean initial LVEF was 24.7%. The mean duration of time the WCD was used after AMI was 91 6 13 days. Left ventricular ejection fraction was re-assessed after 3 months and was found significantly improved to a mean LVEF of 33.6%; and did not improve to beyond 35% in 48 (35%) patients. Seven patients (5%) experienced appropriate WCD shocks for rapid VT or VF; all VT/ VF episodes were terminated successfully with the first WCD shock.
Chung et al. reported the WCD experience among 3569 patients of which 341 patients (12.5% of the total reported cohort) received the device after an AMI with a mean wearing time of 48 days after AMI. 22 
Post-CABG patients
Patients with severely reduced LVEF (LVEF 35%) undergoing CABG have an increased mortality, particularly within the first month (7%). Current guidelines do not recommend ICD implant prior to 3 months after CABG because some patients will have improvement in their LVEF after revascularization and the improvement is unpredictable.
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The largest focused study on this subgroup of patients was that by Zishiri et al. 23 They looked at the use of WCD after revascularization procedures in patients with LVEF 35% and compared 809 patients with WCDs after PCI and CABG from the US National WCD (LifeVest, ZOLL, Pittsburgh, PA, USA) data base with 4149 PCI and CABG patients from the Cleveland Clinic database without WCD use. Three-month mortality after CABG was 3 and 7% in the WCD group and non-WCD cohort, respectively (P ¼ 0.03) and post-PCI 10% vs. 2% (P < 0.0001) in the WCD and non-WCD group, respectively. Wearable cardioverter defibrillator use was associated with adjusted lower risks of long-term mortality in the total cohort (39%, P < 0.0001) and both post-coronary artery bypass graft surgery (38%, P ¼ 0.048) and post-PCI (57%, P < 0.0001) cohorts (mean follow-up: 3.2 years). The incidence of appropriate therapy was 1.3% of patients in the WCD cohort. The German report on patients' post-CABG with low LVEF included 88 patients. 21 Within 3 months post-CABG, six patients (7%)
experienced VT/VF episodes with termination by the first WCD shock. There was no improvement in LVEF in 32 patients (36%) necessitating ICD implants, 42 patients (47%) showed improvement of LVEF and did not receive ICDs. Similarly, in the report by Chung et al., among 243 patients (8.9% of the total WCD cohort of 3569) with a mean WCD wearing time of 1.5 months after CABG procedures, VT/VF events occurred in three patients, two were terminated by the first WCD shock; one patient died during a VF episode. 22 
NICM patients
The WEARIT-II Registry enrolled 2000 patients and included 927 patients with NICM (46%). 24 The other patients included ICM (n ¼ 805, 40%), or congenital/inherited heart disease (n ¼ 268). The median ejection fraction was 25%, with relatively lower EF in the NICM group (20%). There were a total of 120 sustained VT episodes in 41 patients and 54% of these received appropriate WCD shock. Only 10 patients (0.5%) received inappropriate WCD therapy. The rate of sustained VT by 3 months was 3% among patients with ICM and congenital/inherited heart disease, and 1% among NICM patients (P ¼ 0.02). Singh et al. 25 studied 254 patients with newly diagnosed NICM and 271 patients with newly diagnosed ICM with LVEF 35% by echocardiography. During 56.7 patient-years, 0 NICM patients received an appropriate WCD shock, whereas 3 (1.2%) received an inappropriate shock. In the report by Chung et al., of the 3569 patients studied, 546 (20%) patients were noted to have a diagnosis of recent NICM. 22 During a mean WCD wearing time of 56 days, four patients received shocks for VT or VF events.
Specific populations
Bridge to transplant patients Episodes of SCD are not uncommon in patients awaiting heart transplantation 18 or who need ventricular-assist devices. 26 Implantable cardioverter-defibrillator implantation is often recommended as a bridge to heart transplantation or in patients who are candidates for LVADs. However, ICD implantation in these patients is not without risk; complications after ICD implantation are not uncommon, and additional costs with unpredictable length of ICD use have to be considered. Opreanu et al. studied 121 patients awaiting transplantation with a mean ejection fraction was 25%. 27 NICM was the underlying diagnosis in 67(55%) patients, whereas 21(17%) patients had ICM and 33(27%) had a mixed or uncharacterized CMP. Eighty-eight patients (73%) were being evaluated for or were on a transplant waiting list, and 33 patients (27%) had a prior transplant, experienced rejection, and were awaiting re-transplantation. The patients wore the WCD for an average of 127 6 392 days with average daily use of 17 6 7 h (median: 20 h). Seven patients (6%) received appropriate WCD shocks. Fifty-one patients (42%) ended use after ICD implantation and 13 patients (11%) after transplant. Klein et al. included 22 patients on the waiting list for heart transplantation with WCD use. 21 Two patients had shocks for VT/VF during a mean wearing time of 5.4 months. ICD implantation was performed later in seven patients; three patients had transplantation withheld because of LV function improvement and four patients preferred ICD implantation instead of continuing with the WCD for an unpredictable waiting time. The International Society of Heart and Lung Transplantation Guidelines 2006 recommend (class I, level of evidence C) to use the WCD as a temporary bridge for patients at home awaiting heart transplantation. 18 Peri-partum cardiomyopathy patients Peri-partum cardiomyopathy is a rare myocardial disease that can develop within the last month of pregnancy or within the first 6 months after delivery and has a variable prognosis with full recovery of LVEF within 6 months is reported in about 50%. Cases of LVEF 25% have a poor prognosis with a high mortality rate (19%) and need for heart transplantation in 6-11%; the mode of death was HF in 45%; SCD occurred in 38%. 28 Improvement of LVEF to >45% within 2 months predicts full functional LV recovery. Saltzberg et al. performed a retrospective analysis comparing 107 peri-partum cardiomyopathy patients with matched non-pregnant women with NICM (159 patients). 29 WCD use averaged 124 6 123 days and 96 6 83 days among peri-partum and NICM patients, respectively. Patients in the peri-partum group had no appropriate shocks for VT/VF while one NICM patient received two successful shocks. Subsequently, Duncket et al. reported a prospective series among seven patients with per-partum cardiomyopathy that received WCDs 30 . During a median WCD follow-up of 81 days appropriate and successful WCD shocks occurred in three of the seven women. No SCD occurred in women not using the WCD during a median follow-up of 12 months.
Post-ICD extraction patients
Current guidelines for CDIs treatment advocate the removal of both the device and leads because they serve as a reservoir for infection, except in cases of incisional or superficial infections. 31 Antibiotic treatment of CDI is recommended for 10-14 days after device removal for pocket site and bloodstream infection and 4-6 weeks for complicated infections. Thus, patients are generally discharged from the hospital before device re-implantation. Once discharged, provisions to protect patients from the risk of SCD until reimplantation are warranted. A WCD might be an alternative for this group of patients. Tanawuttiwat et al. studied 97 patients (mean age 62.8 6 13.3) who were prescribed a WCD after ICD removal. 32 The median duration of antibiotic use was 14.7 days (10-30) . The median daily WCD use was 20 h/day and the median length of use was 21 days (5-47). A total of three patients were shocked by WCD. Two patients had four episodes of VT successfully terminated by the WCD and one patient experienced inappropriate shocks. Three patients experienced SCD outside the hospital while not wearing the device.
We recently reported an analysis of 8058 patients (mean age 62 6 14 years, male 75%) who received the WCD post-ICD system extraction for infection. 33 Median time to re-implantation of an ICD was 50 days (IQR: 24-83 days). While wearing the WCD, 334 (4%) patients experienced 406 VT/VF events, of which 348 events were treated by the WCD and 54 events averted by conscious patients using the response buttons. The overall 24-h survival, both treated and non-treated, was 93% (312/334). Ventricular tachycardia/ventricular fibrillation occurrence was the highest in the initial weeks following ICD removal (0.9, 0.7, and 0.7% per week for weeks 1, 2, and 3, respectively). The 2-month cumulative event rate was 4% and up to 10% at 1 year. For all patients, the 30-day post-event survival was 81% and 90-day was 75%. An ICD was re-implanted in 80% of patients.
Compliance with the WCD
In the original experience of the WCD (which combined the WEARIT and BIROAD studies), 68 of 289 patients (24.5%) stopped wearing the WCD. 19 In the WEARIT population, 30% of those who discontinued the use of the device did so due to comfort or lifestyle issues. In contrast, the major cause of discontinuing the device in the BIROAD study, 11% of patients stopped wearing the device because of discomfort or because they felt it altered their lifestyle. There were five SCDs that occurred when patients were not wearing the device. Four patients were non-compliant with low daily device use. They concluded that since the size and weight of the device used in the study was the principal reason for non-compliance, and reduction in size and weight may be expected to improve compliance. Chung et al. reported on the compliance patterns in 2208 of the 3569 patients included in their series with the subsequent generation of the WCD which was 40% smaller in size and weight. 22 The median daily use of the WCD was 21.7 h (91% of time available), mean daily use was 19.9 6 4.7 h, (range 0.4-25.9 h), daily use was >90% in 52% of patients and >80% in 71% of patients. Of 2169 patients with recorded data, 307 (14.2%) stopped wearing it prematurely because of comfort issues or adverse reactions, primarily related to the size and weight of the monitor. Longer duration of monitoring correlated with higher compliance rates. Patients using the device >60 days (n ¼ 599) averaged 20.8 6 3.7 h per day, as compared with those using it between 45 and 60 days (P < 0.05). Patients using it <15 days (n ¼ 160) averaged 17.2 6 5.9 h, significantly less than all other groups (P < 0.001). In this study, 14 .2% stopped wearing the WCD because of comfort issues or adverse reactions. Improved compliance in comparison to the original experience may have been seen because the WCD used in this study was 40% smaller in size and weight.
No systematic studies on the psychological impact of using the wearable defibrillator have been published. Klein et al. reported favourable results among 60 patients in their series. 21 Almost all patients in this series reported that the wearable defibrillator provided them with a sense of security that was important. However, about half of the patients reported sleep disturbances, mainly caused by false alarms which occurred once every 13 days on average. 21 
Future directions
Although WCD therapy has been widely adopted at an increasing rate in clinical practice, only preliminary data exist on the actual effectiveness of this intervention in improving survival among patients who are at risk for SCD. Well-conducted randomized trials in select population with appropriate endpoints are strongly needed to demonstrate the true benefit of WCDs. The Vest Prevention of Early Sudden Death (VEST) trial is designed to determine whether a WCD can decrease mortality in the first 2 months after an MI, prior to the time an ICD is indicated. This trial had enrolled >700 patients by 2015, with completion expected by the end of 2016 (NCT01446965). 34 The Study of the Wearable Defibrillator in Heart-Failure Patients (SWIFT; NCT01326624) is another ongoing observational study to evaluate rates of defibrillation in four important subgroups: advanced HF, LVEF 35% with revascularization or HF diagnosis within 90 days, Killip class III to IV AMI, and those awaiting ICD reimplantation. 35 An unanswered question about the use of WCD is its costeffectiveness. In our current cost conscious healthcare system, treatment modalities must be compared on the basis of whether they are clinically effective as well as economically favourable. Costeffectiveness will be influenced largely by the number of patients needed to treat to prevent 1 arrhythmic event or death. Improved risk stratification to minimize use in low-risk patients would therefore dramatically improve the overall cost per life saved. In the US, Medicare and other insurance providers cover most WCD indications. In European countries with WCD experience, the WCD system is rented from Zoll, for the duration of the wearing period and is reimbursed by insurance companies after detailed review of the patient's medical condition. Healy and Carrillo 36 performed a costeffectiveness analysis of WCD use among patients undergoing ICD explant and reported that the WCD was economically favourable when used for at least for 2 weeks after ICD explant. They concluded that the cost-effectiveness ratio is time-sensitive and positively related to the risk of SCD. In another analysis by Saunders et al. among WCD receipts in patients post-MI with reduced LVEF, the WCD strategy was more expensive than usual care (incremental cost of $11 503), but improved life expectancy by 0.261 life years or 0.190 quality-adjusted life years (QALYs). 37 Based on their analysis, the use of the WCD cost less than $100 000 per QALY gained as long as the rate of cardiac arrest in the first month post-MI was >1.163% and hence they suggested that for patients who have had a recent MI and have reduced LVEF, use of a WCD could reduce the rate of SCD during the recovery period at a cost that appears to be economically attractive. More portable devices with more advanced sensing algorithms may increase healthcare efficiency by improving Indications and use of the wearable cardiac defibrillator patient compliance and tolerability, improved care delivery, access to technology, and lower cost. Despite the above, it is important to realize that the WCD is a tool available to physicians, allowing us to perform a thorough and protected risk stratification, and not an alternative to permanent ICD implantation. It offers a 'way out' in situations where further risk stratification is necessary.
Conclusions
Sudden cardiac death resulting from VT/VF remains an important and potentially preventable cause of death. Wearable cardioverter defibrillators can serve as safe and effective approach for aborting arrhythmic death among patients known to be at high risk of sudden arrhythmic death, yet do not fulfil accepted criteria for immediate ICD implantation or who have a transient barrier to permanent device implantation. Furthermore, the WCD system can used in patients when risk stratification needs more time for final therapy decision; it helps to avoid unnecessary ICD implantation. Further research in the form of prospective registries and randomized trials are needed to better guide the optimal use of WCD therapy.
